Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?

Journal of Critical Care

Volumn 28, Issue 6, 2013, Pages 970-974

  Pereira, José Manuel ^a,b   Teixeira Pinto, Armando ^c   Basílio, Carla ^a   Sousa Dias, Conceição ^a   Mergulhão, Paulo ^a,b   Paiva, José Artur ^a,b  

^a Centro Hospitalar Universitário de São João   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bacteremia; Biomarkers; Community acquired pneumonia; Pneumococcus; Procalcitonin

Indexed keywords

BETA LACTAM; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CEPHALOSPORIN; D DIMER; HYDROCORTISONE; LACTIC ACID; MACROLIDE; PROCALCITONIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS PNEUMONIA;

25TH TO 75TH INTERQUARTILE RANGE; AREA UNDER THE RECEIVER OPERATING CHARACTERISTICS CURVE; AROC; BACTEREMIA; BIOMARKERS; BNP; BRAIN NATRIURETIC PEPTIDE; C-REACTIVE PROTEIN; CAP; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; COPD; CRP; ICU; INTENSIVE CARE UNIT; IQR; LEUKOCYTE COUNT; PCT; PIRO; PNEUMOCOCCUS; PNEUMONIA SEVERITY INDEX; PREDISPOSITION, INSULT, RESPONSE, ORGAN FAILURE; PROCALCITONIN; PSI; RECEIVER OPERATING CHARACTERISTICS; ROC; SAPS; SD; SEPSIS-RELATED ORGAN FAILURE ASSESSMENT; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SOFA; SOLUBLE FORM OF TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; STANDARD DEVIATION; STREM; WBC;

BACTEREMIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LACTATES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PNEUMONIA, PNEUMOCOCCAL; PORTUGAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 84887385450     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2013.04.016     Document Type: Article

References (33)

1. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122:130-141.
2. Angus D.C., Marrie T.J., Obrosky D.S., et al. Severe community-acquired pneumonia: Use of intensive care services and evaluation of American and British thoracic society diagnosis criteria. Am J Respir Crit Care Med 2002, 166:717-723.
3. Ramirez J.A. Community-Acquired Pneumonia Organization Investigators: worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. Semin Respir Crit Care Med 2005, 26:543-552.
4. Bodi M., Rodriguez A., Solé-Violán J., et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Disease Society of America guidelines on survival. Clin Infect Dis 2005, 41:1709-1716.
5. Musher D.M., Alexandraki I., Graviss E.A., et al. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 2000, 79:210-221.
6. Afessa B., Greaves W.L., Frederick W.R. Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital. Clin Infect Dis 1995, 21:345-351.
7. Burman L.A., Norrby R., Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis 1985, 7:133-142.
8. Hook E.W.D., Horton C.A., Schaberg D.R. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983, 249:1055-1057.
9. Kramer M.R., Rudensky B., Hadas-Halperin I., et al. Pneumococcal bacteremia - no change in mortality in 30 years: analysis of 104 cases and review of the literature. Isr J Med Sci 1987, 23:174-180.
10. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Disease Society of American/American Thoracic Society consensus guidelines for the management of community acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-72.
11. Lim W.S., Baudouin S.V., George R.C., et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64(Suppl 3):iii1-55.
12. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011, 17(Suppl 6):E1-59.
13. Mufson M.A., Stanek R.J. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999, 107(1A):34S-43S.
14. Baddour L.M., Yu V.L., Klugman K.P., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-444.
15. Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161:1837-1842.
16. Martinez J.A., Horcajada J.P., Almela M., et al. Addition of a macrolide to a b-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36:389-395.
17. Weiss K., Low D.E., Cortes L., et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae in adults. Can Respir J 2004, 11:589-593.
18. Rodriguez A., Mendia A., Sirvent J.M., et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35:1493-1498.
19. Martin-Loeches I., Lisboa T., Rodriguez A., et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010, 36:612-620.
20. Yu V., Chiou C., Feldman C., et al. An international prospective study of pneumococcal pneumonia: correlation with in vitro resistance, antibiotics administered and clinical outcome. Clin Infect Dis 2003, 37:230-237.
21. Le Gall J.R., Lemeshow S., Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963.
22. Moreno R.P., Metnitz P.G., Almeida E., et al. SAPS 3-from evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 2005, 31:1345-1355.
23. Rello J., Rodriguez A., Lisboa T., et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 2009, 37:456-462.
24. Vincent J.L., Moreno R., Takala J., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
25. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Eng J Med 1997, 336:243-250.
26. Marrie T.J., Low D.E., de Carolis E., et al. A comparison of bacteremic pneumococcal pneumonia of any etiology: results from a Canadian multicenter study. Can Respir J 2003, 10:368-374.
27. Bordon J., Peyrani P., Brock G.N., et al. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia. Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Chest 2008, 133:618-624.
28. Almirall J., Bolíbar I., Toran P., et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
29. Menéndez R., Sahuquillo-Arce J.M., Reyes S., et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012, 141:1537-1545.
30. Prat C., Dominguez J., Andreo F., et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 2006, 52:169-177.
31. Lacoma A., Rodríguez N., Prat C., et al. Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2012, 31:825-833.
32. Müller F., Christ-Crain M., Bregenzer T., et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010, 138:121-129.
33. Schuetz P., Stolz D., Mueller B., et al. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community-acquired pneumonia. BMC Infect Dis 2008, 8:22.